Cargando…

Statins affect ETS1-overexpressing triple-negative breast cancer cells by restoring DUSP4 deficiency

We investigated the molecular mechanisms underlying statin-induced growth suppression of triple-negative breast cancer (TNBC) that overexpress the transcription factor ets proto-oncogene 1(ets-1) and downregulate dual specific protein phosphatase 4(dusp4) expression. We examined the gene expression...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jung, Hae Hyun, Lee, Soo-Hyeon, Kim, Ji-Yeon, Ahn, Jin Seok, Park, Yeon Hee, Im, Young-Hyuck
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5015082/ https://www.ncbi.nlm.nih.gov/pubmed/27604655 http://dx.doi.org/10.1038/srep33035

Ejemplares similares

Genomic characteristics of triple negative apocrine carcinoma: a comparison to triple negative breast cancer
por: Kim, Ji-Yeon, et al.
Publicado: (2023)

Prognostic value of ERBB4 expression in patients with triple negative breast cancer
por: Kim, Ji-Yeon, et al.
Publicado: (2016)

The relationship between nuclear factor (NF)-κB family gene expression and prognosis in triple-negative breast cancer (TNBC) patients receiving adjuvant doxorubicin treatment
por: Kim, Ji-Yeon, et al.
Publicado: (2016)

Association between Mutation and Expression of TP53 as a Potential Prognostic Marker of Triple-Negative Breast Cancer
por: Kim, Ji-Yeon, et al.
Publicado: (2016)

Lymphocyte-activating gene 3 expression in tumor cells predicts immune checkpoint inhibitor response in triple negative breast cancer
por: Kim, Ji-Yeon, et al.
Publicado: (2023)

A Retrospective Exploratory Analysis for Serum Extracellular Vesicles Reveals APRIL (TNFSF13), CXCL13, and VEGF-A as Prognostic Biomarkers for Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer
por: Jung, Hae Hyun, et al.
Publicado: (2023)

Real World Experience of Second-Line Treatment Strategies after Palbociclib and Letrozole: Overall Survival in Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer
por: Kim, Ji-Yeon, et al.
Publicado: (2023)

Which Clinicopathologic Parameters Suggest Primary Resistance to Palbociclib in Combination With Letrozole as the First-Line Treatment for Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer?
por: Kim, Ji-Yeon, et al.
Publicado: (2021)

Real-World Data from a Refractory Triple-Negative Breast Cancer Cohort Selected Using a Clinical Data Warehouse Approach
por: Kim, Hana, et al.
Publicado: (2021)

DUSP1 promoter methylation in peripheral blood leukocyte is associated with triple-negative breast cancer risk
por: Li, Jing, et al.
Publicado: (2017)

Triple-negative, basal-like, and quintuple-negative breast cancers: better prediction model for survival
por: Choi, Yoon-La, et al.
Publicado: (2010)

The Role of Chemotherapy in Patients With HER2-Negative Isolated Locoregional Recurrence of Breast Cancer: A Multicenter Retrospective Cohort Study
por: Lee, Kyoungmin, et al.
Publicado: (2021)

Nuclear-Biased DUSP6 Expression is Associated with Cancer Spreading Including Brain Metastasis in Triple-Negative Breast Cancer
por: Wu, Fan, et al.
Publicado: (2019)

Favorable response to doxorubicin combination chemotherapy does not yield good clinical outcome in patients with metastatic breast cancer with triple-negative phenotype
por: Yi, Seong Yoon, et al.
Publicado: (2010)

Impact of Statin Use on Outcomes in Triple Negative Breast Cancer
por: Shaitelman, Simona F., et al.
Publicado: (2017)

Does guideline non-adherence result in worse clinical outcomes for hormone receptor-positive and HER2-negative metastatic breast cancer in premenopausal women?: result of an institution database from South Korea
por: Kim, Hee Kyung, et al.
Publicado: (2019)

The effect of androgen receptor expression on clinical characterization of metastatic breast cancer
por: Kim, Ji-Yeon, et al.
Publicado: (2017)

Clinical implications of genomic profiles in metastatic breast cancer with a focus on TP53 and PIK3CA, the most frequently mutated genes
por: Kim, Ji-Yeon, et al.
Publicado: (2017)

Immune signature of metastatic breast cancer: Identifying predictive markers of immunotherapy response
por: Kim, Ji-Yeon, et al.
Publicado: (2017)

Targeting Cancer Stem Cells in Triple-Negative Breast Cancer
por: Park, So-Yeon, et al.
Publicado: (2019)

Identification of DUSP4/6 overexpression as a potential rheostat to NRAS-induced hepatocarcinogenesis
por: Klemm, Sophie, et al.
Publicado: (2023)

DUSP5 and DUSP6 modulate corneal epithelial cell proliferation
por: Wang, Zheng, et al.
Publicado: (2010)

DUSP6 Deficiency Attenuates Neurodegeneration after Global Cerebral Ischemia
por: Weng, Yi-Chinn, et al.
Publicado: (2023)

The Impacts of Inclusion in Clinical Trials on Outcomes among Patients with Metastatic Breast Cancer (MBC)
por: Lee, Ji Yun, et al.
Publicado: (2016)

Correction: triple-negative, basal-like, and quintuple-negative breast cancers: better prediction model for survival
por: Choi, Yoon-La, et al.
Publicado: (2011)

Negative-feedback regulation of FGF signalling by DUSP6/MKP-3 is driven by ERK1/2 and mediated by Ets factor binding to a conserved site within the DUSP6/MKP-3 gene promoter
por: Ekerot, Maria, et al.
Publicado: (2008)

Statins inhibit proliferation and induce apoptosis in triple-negative breast cancer cells
por: O’Grady, Shane, et al.
Publicado: (2022)

Evaluation of Pathologic Complete Response in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: Experience in a Single Institution over a 10-Year Period
por: Choi, Misun, et al.
Publicado: (2017)

PIK3CA Mutations and Neoadjuvant Therapy Outcome in Patients with Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: A Sequential Analysis
por: Seo, Youjeong, et al.
Publicado: (2018)

Overexpression of the cancer-related DUSP1 gene in human obesity and its modulation by physical exercise
por: Khadir, Abdelkrim, et al.
Publicado: (2014)

Clinical activity of fulvestrant in metastatic breast cancer previously treated with endocrine therapy and/or chemotherapy
por: Heo, Mi Hwa, et al.
Publicado: (2019)

Clinical Characteristics of Korean Breast Cancer Patients Who Carry Pathogenic Germline Mutations in Both BRCA1 and BRCA2: A Single-Center Experience
por: Hur, Joon Young, et al.
Publicado: (2020)

Statins and the risk of gastric cancer in diabetes patients
por: Lee, Jeeyun, et al.
Publicado: (2012)

Elevated Level of Nerve Growth Factor (NGF) in Serum-Derived Exosomes Predicts Poor Survival in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy
por: Jung, Hae Hyun, et al.
Publicado: (2021)

Implications of Tamoxifen Resistance in Palbociclib Efficacy for Patients with Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer: Subgroup Analyses of KCSG-BR15-10 (YoungPEARL)
por: Lee, Jiyun, et al.
Publicado: (2021)

Overexpression of DUSP6 enhances chemotherapy-resistance of ovarian epithelial cancer by regulating the ERK signaling pathway
por: Gao, Yan, et al.
Publicado: (2020)

Anti-tumor activity of BET inhibitors in androgen-receptor-expressing triple-negative breast cancer
por: Park, In Hae, et al.
Publicado: (2019)

DUSPs, to MAP kinases and beyond
por: Huang, Ching-Yu, et al.
Publicado: (2012)

CD24 Overexpression Is Associated with Poor Prognosis in Luminal A and Triple-Negative Breast Cancer
por: Kwon, Mi Jeong, et al.
Publicado: (2015)

Quality of life outcomes including neuropathy-associated scale from a phase II, multicenter, randomized trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy for HER2-negative metastatic breast cancer: Korean Cancer Study Group Trial (KCSG BR13-11)
por: Kim, Ji-Yeon, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_m01imedi5j2q5q0gs9lb1q8d06